• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Antiviral chemistry & chemotherapy >Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2008 (2nd edition): RNA viruses.
【24h】

Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2008 (2nd edition): RNA viruses.

机译：抗病毒化学和化学疗法当前的抗病毒剂FactFile 2008（第2版）：RNA病毒。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Among the RNA viruses, other than the retroviruses (that is, HIV), which are dealt with separately in the current FactFile, the most important targets for the development of antiviral agents at the moment are the orthomyxoviruses (that is, influenza), the hepaciviruses (that is, hepatitis C virus [HCV]) and, to a lesser extent, the picornaviruses. Although the uncoating inhibitors amantadine and rimantadine were the first known inhibitors of influenza A, the neuraminidase inhibitors oseltamivir, zanamivir and peramivir have now become the prime antiviral drugs for the treatment of influenza A and B virus infections. For HCV infections, standard treatment consists of the combination of pegylated interferon-alpha with ribavirin, but several other antivirals targeted at specific viral functions such as the HCV protease and/ or polymerase may be expected to soon take an important share of this important market. Still untapped is the potential of a variety of uncoating inhibitors, as well as protease and/orpolymerase inhibitors against the wide spectrum of picornaviruses. While ribavirin has been available for 35 years as a broad-spectrum anti-RNA virus agent, relatively new and unexplored is favipiravir (T-705) accredited with activity against influenza as well as flaviviruses, bunyaviruses and arenaviruses.
机译：在RNA病毒中，除了在当前FactFile中单独处理的逆转录病毒（即HIV）之外，目前抗病毒药物开发的最重要目标是正粘病毒（即流感），乙型肝炎病毒（即丙型肝炎病毒[HCV]），以及程度较小的小核糖核酸病毒。尽管脱膜抑制剂金刚烷胺和金刚乙胺是最早已知的甲型流感抑制剂，但神经氨酸酶抑制剂奥司他韦，扎那米韦和帕拉米韦现已成为治疗甲型和乙型流感病毒的主要抗病毒药物。对于HCV感染，标准治疗包括聚乙二醇化干扰素-α和利巴韦林的组合，但是预计其他针对特定病毒功能的其他抗病毒药（例如HCV蛋白酶和/或聚合酶）很快将在这一重要市场中占据重要份额。尚未发现的是各种脱膜抑制剂以及针对广泛的小核糖核酸病毒的蛋白酶和/或聚合酶抑制剂的潜力。尽管利巴韦林作为广谱抗RNA病毒剂已有35年的历史了，但相对较新且尚未开发的是具有抗流感以及黄病毒，布尼亚病毒和沙粒病毒活性的favipiravir（T-705）。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号